RxDoctor Payments Data

John Paul Kelada, MD

Family Medicine · Roseville, CANPI 1013396118

Payments from drug & device makers

$15,540in general payments, 2019–2025

Across 804 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • Astellas Pharma US Inc$995
  • Pfizer$880
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,03497%
  • Education$5063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk104$1,543
AbbVie79$1,473
GSK75$1,347
Boehringer Ingelheim62$1,159
Astellas Pharma US Inc33$995
Pfizer41$880
Bayer29$853
Lilly USA, LLC47$807
AstraZeneca40$797
Merck28$535
Novartis23$486
Johnson & Johnson18$394
Viiv Healthcare Company16$346
Exact Sciences15$329
Amgen14$284
Abbott15$230
Amarin Pharma, Inc.18$222
Biohaven Pharmaceuticals, Inc.12$199
Corcept Therapeutics7$165
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$151
Sanofi-aventis U.S. LLC10$148
Otsuka America Pharmaceutical, Inc.7$133
Biohaven Pharmaceutical Holding Company Ltd.11$132
Sanofi Pasteur Inc.5$128
Medtronic4$91
Arbor Pharmaceuticals, Inc.2$87
Teva Pharmaceuticals USA, Inc.4$83
Gilead4$80
Ironwood Pharmaceuticals, Inc5$80
E.r. Squibb & Sons, L.L.C.4$72
Neuronetics, Inc.1$71
Hologic Sales And Service, LLC4$71
Dexcom, Inc.2$68
Sequel Med Tech, LLC2$67
Organon3$65
Agios Pharmaceuticals, Inc.2$63
Tandem Diabetes Care, Inc.2$60
Aimmune Therapeutics, Inc.2$52
Nestle Healthcare Nutrition Inc.2$51
Alfasigma USA, Inc.3$50
Esperion Therapeutics, Inc.3$45
Alk-abello, Inc2$40
Coopersurgical, Inc.2$40
Seqirus USA Inc3$40
Avanir Pharmaceuticals, Inc.2$39
Takeda Pharmaceuticals U.S.A., Inc.2$36
Kowa Pharmaceuticals America, Inc.2$35
Mayne Pharma Commercial LLC3$34
Phathom Pharmaceuticals, Inc.2$33
Almatica Pharma LLC1$32
VBI Vaccine (delaware) Inc.1$28
Eisai Inc.2$28
Sumitomo Pharma America, Inc.1$27
Bausch Health US, LLC2$25
Axsome Therapeutics, Inc.1$23
Vertex1$21
Radius Health, Inc.1$19
Scilex Pharmaceuticals Inc.1$18
Electromed, Inc.1$18
Edwards Lifesciences1$18

How this compares

$15,540 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$264,201
Medicare patients
485
Services billed
3,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide188$260,439
JardianceEmpagliflozin161$221,264
EliquisApixaban168$198,586
RybelsusSemaglutide67$118,183
Synjardy XrEmpagliflozin/Metformin Hcl81$103,155
EntrestoSacubitril/Valsartan34$59,548
FarxigaDapagliflozin Propanediol50$53,060
MounjaroTirzepatide36$41,210
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$39,838
Trijardy XrEmpaglifloz/Linaglip/Metformin14$20,173
MyrbetriqMirabegron13$15,545
Soliqua 100-33Insulin Glargine/Lixisenatide18$15,093
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$14,169
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,230
Atorvastatin Calcium632$7,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,543$378,622255 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Stiolto Respimat$1,159$358,761272 claims
PfizerEliquis$880$198,586168 claims
NovartisEntresto$486$59,54834 claims
AstraZenecaFarxiga, Symbicort$797$55,59762 claims
Lilly USA, LLCMounjaro$807$41,21036 claims
GSKTrelegy Ellipta$1,347$39,83850 claims
Astellas Pharma US IncMyrbetriq$995$15,54513 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$148$15,09318 claims
AbbVieSynthroid$1,473$5,42259 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →